Highlights Checkpoint Therapeutics, Inc.

Equities

CKPT

US1628282063

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
2.03 ^USD	+7.98%		+31.82%	-11.35%

May. 10	Checkpoint Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 22	Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Checkpoint Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
U.S. Food and Drug Administration Issues Complete Response Letter for Checkpoint Therapeutics, Inc.'s Cosibelimab Solely Due to Inspection Findings At Third-Party Manufacturer	Dec. 18	CI
US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy	Dec. 18	RE
Checkpoint Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer	23-10-18	CI
Checkpoint Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Checkpoint Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma	23-03-02	CI
Checkpoint Therapeutics Submits Biologics License Application for Skin Cancer Therapy	23-01-04	MT
Checkpoint Therapeutics, Inc. Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma	23-01-04	CI
Checkpoint Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
Checkpoint Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Checkpoint Therapeutics, Inc. Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma	22-06-16	CI
Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Skin Cancer Drug Candidate	22-05-13	MT
Checkpoint Therapeutics Inc. Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency	22-05-13	CI
Checkpoint Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-28	CI
Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma	22-01-25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Checkpoint Therapeutics, Inc.

Equities

CKPT

US1628282063

Highlights

Filters